Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental Parkinsonism

Neuroscience

Volumn 81, Issue 2, 1997, Pages 399-404

  Bezard, E ^a   Boraud, T ^a   Bioulac, B ^a   Gross, C E ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Compensatory mechanisms; Glutamate; Monkey; MPTP; Slow evolution of disease; Stereotaxic intracranial injection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; KYNURENIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE ASSOCIATION; MONKEY; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; STEREOTAXIS; SUBSTANTIA NIGRA;

ANIMALS; DISEASE MODELS, ANIMAL; GLUTAMIC ACID; KYNURENIC ACID; MACACA; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0031559937     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00226-1     Document Type: Article

References (48)

1. Agid Y. Parkinson's disease: pathophysiology. Lancet. 337:1991;1321-1323.
2. Alexander G. E., Crutcher M. D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
3. Bankiewicz K. S., Oldfield E. H., Chiueh C. C., Doppamn J. L., Jacobowitz D. M., Kopin I. J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of MPTP. Life Sci. 39:1986;7-16.
4. Benazzouz A., Boraud T., Stutzmann J. M., Gross C. Riluzole prevents MPTP-induced Parkinsonism in the rhesus monkey: a preliminary study. Eur. J. Pharmac. 284:1995;299-307.
5. Benazzouz A., Gross C., Feger J., Boraud T., Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high frequency stimulation in MPTP-treated monkeys. Eur. J. Neurosci. 5:1993;382-389.
6. Bergman H., Wichmann T., Karmon B., Delong M. R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of Parkinsonism. J. Neurophysiol. 72:1994;507-520.
7. Bezard E., Boraud T., Bioulac B., Dufy B., Gross C. E. Blockage of SNc glutamatergic inputs, a new base for presymtomatic diagnosis in Parkinson's disease? Soc. Neurosci. Abstr. 22:1996;2130.
8. Bezard E., Boraud T., Bioulac B., Gross C. E. Presymptomatic revelation of experimental Parkinsonism. NeuroReport. 8:1997;435-438.
9. Bezard E., Dovero S., Bioulac B. and Gross C. (1997) Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci. Lett. (In press).
10. Bezard E., Imbert C., Deloire X., Bioulac B. and Gross C. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in monkey. Brain Res. (In press).
11. Carter C. J. Glutamatergic pathways from the medial prefrontal cortex to the anterior striatum, nucleus accumbens, and substantia nigra. Br. J. Pharmac. 70:1980;50P.
12. Chergui K., Akaoka H., Charlety P. J., Buda M., Chouvet G. Subthalamic nucleus modulates burst firing of nigral dopamine neurons via NMDA receptors. NeuroReport. 5:1994;1185-1188.
13. Chergui K., Charlety P. L., Akaoka H., Saunier C. F., Brunet J. L., Buda M., Svensson T. H., Chouvet G. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur. J. Neurosci. 5:1993;137-144.
14. DeLong M. R. Primates models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
15. DiLoreto S., Florio T., Scarnati E. Evidence that non-NMDA receptors are involved in the excitatory pathway from the pedunculopontine region to nigrostriatal dopaminergic neurons. Expl Brain Res. 89:1992;79-86.
16. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38:1960;1236-1239.
17. Féger J., Ohye C., Gallouin F. and Albe-Fessard D. (1975) Stereotaxic technique for stimulation and recording in nonanaesthetized monkeys: application to the determination of connections between caudate nucleus and substantia nigra. In Advances in Neurology (eds Meldrum B. S. and Marsden C. D.), Vol. 10, pp. 35-45. Raven, New York.
18. Fiedler J., Bustos G. Cortical ablation reduces veratridine evoked release of endogenous glutamate from superfused nigra slices. Neurosci. Lett. 22:1991;96-98.
19. Futami T., Takakusaki K., Kita S. T. Glutamatergic and cholinergic inputs from the pedunculopontine tegmental nucleus to dopamine neurons in the substantia nigra pars compacta. Neurosci. Res. 21:1995;331-342.
20. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. neural Transm. 103:1996;987-1041.
21. Grace A. A., Bunney B. S. The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci. 4:1984;2877-2890.
22. Graham W. C., Robertson R. G., Sambrook M. A., Crossman A. R. Injection of excitatory amino acid antagonists into the pallidal segment of the MPTP-treated primate reverses motor symptoms of Parkinsonism. Life Sci. 47:1990;91-97.
23. Gross C., Bezard E., Boraud T., Bioulac B. Compensatory effects of glutamatergic inputs to the SNc in MPTP-treated monkeys. Soc. Neurosci. Abstr. 22:1996;216.
24. Gross C., Bezard E., Boraud T., Bioulac B. Glutamate, a new approach to the physiopathology and treatment of Parkinson's disease. Archs Physiol. Biochem. 104:1996;35.
25. Jackson A., Crossman A. R. Nucleus tegmenti pedunculopontinus efferent connections with special reference to the basal ganglia, studied in the rat by anterograde and retrograde transport of horseradish peroxidase. Neuroscience. 10:1983;725-765.
26. Jackson-Lewis V., Jakowec M., Burke R. E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4:1995;257-269.
27. Kita H., Kita S. T. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J. comp. Neurol. 260:1987;435-452.
28. Kornhuber J., Jin-Soo K., Kornhuber M. E., Kornhuber H. H. The corticonigral projection: reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat. Brain Res. 322:1984;124-126.
29. Lavoie B., Parent A. Pedunculopontine nucleus in the squirrel monkey: cholinergic and glutamatergic projections to the substantia nigra. J. comp. Neurol. 344:1994;232-241.
30. Lee C. S., Schulzer M., Mak E. K., Snow B. J., Tsui J. K., Calne S., Hammerstad J., Calne D. B. Clinical observations on the rate of progression of idiopathic Parkinsonism. Brain. 117:1994;501-507.
31. Matsumura M., Kojima J., Yamaji Y., Imai H., Takada M., Tokuno H., Nambu A., Inase M. Hemiparkinsonism in macaque monkeys produced by lesioning the pedunculopontine tegmental nucleus. Mov. Disord. 12(Suppl. 1):1997;94.
32. Miller W. C. and Long M. R. D. (1987) Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of Parkinsonism. In Basal Ganglia II (eds Carpenter M. B. and Jayaraman A.), Vol. 32, pp. 415-427. Plenum, New York.
33. Mitchell I. J., Clarke C. E., Boyce S., Robertson R. G., Peggs D., Sambrook M. A., Crossman A. R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 32:1989;213-226.
34. Overton P., Clark D. Iontophoretically administred drugs acting at the NMDA receptor modulate burst firing in A9 dopamine neurons in the rat. Synapse. 10:1992;131-140.
35. Overton P. G., O'Callaghan J. F. X., Greenfield S. A. Possible intermixing of neurons from the subthalamic nucleus and substantia nigra pars compacta in the guinea-pig. Expl Brain Res. 107:1995;151-165.
36. Parent A., Hazrati L. N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Rev. 20:1995;128-154.
37. Robertson R. G., Farmery S. M., Sambrook M. A., Crossman A. R. Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res. 476:1989;317-322.
38. Scarnati E., Proia A., Campana E., Pacitti C. A microiontophoretic study on the nature of the putative synaptic neurotransmitter involved in the pedunculopontine-substantia nigra pars compacta excitatory pathway of the rat. Expl Brain Res. 62:1986;470-478.
39. Schneider J. S., Yuwiler A., Markham C. H. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res. 411:1987;144-150.
40. Schulzer M., Lee C. S., Mak E. K., Vingerhoets F. J. G., Calne D. B. A mathematical model of pathogenesis in idiopathic Parkinsonism. Brain. 117:1994;509-516.
41. Smith I. D., Grace A. A. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse. 12:1992;287-303.
42. Smith Y., Hazrati L. N., Parent A. Efferent projections of the subthalamic nucleus in the squirrel monkey as studied by the PHA-L anterograde tracing method. J. comp. Neurol. 259:1990;306-323.
43. Smith Y., Paquet M., Charara A., Parent A., Soghomonian J. J. Glutamate inputs to midbrain dopaminergic neurones in primates: synaptic relationships and localization of glutamate receptor subunits. Mov. Disord. 12(Suppl. 1):1997;139.
44. Starr M. S. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
45. Stern Y. MPTP-induced Parkinsonism. Prog. Neurobiol. 34:1990;107-114.
46. Szabo J., Cowan W. M. A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J. comp. Neurol. 222:1984;265-300.
47. Taylor J. R., Elsworth J. D., Roth R. H., Sladek J. R. and Redmond D. E. (1994) Behavioral effects of MPTP administration in the Vervet monkey, a primate model of Parkinson's disease. In Toxin-induced Models of Neurological Disorders (eds Woodruff M. L. and Nonneman A.), pp. 139-151. Plenum, New York.
48. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A., Stricker E. M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13:1990;290-296.